Hidradenitis Suppurativa: Why Recurring Boils Need Early Treatment

You notice a painful lump in your armpit. It comes and goes. Then another appears in your groin. You assume it's a temporary infection, something that will clear on its own. But months later, the lumps return. They're deeper now, more tender. They leave marks. This cycle—boils, healing, scarring, boils again—is the lived reality of hidradenitis suppurativa, a chronic skin condition that affects roughly one in every hundred people worldwide, yet remains largely invisible in public conversation.

Hidradenitis suppurativa, or HS, is characterized by painful nodules, abscesses, and persistent scarring that typically develop in areas where skin folds and creates friction: the armpits, under the breasts, the groin, the space between the buttocks. The condition is not contagious. It is not a sign of poor hygiene. Yet many people live with it for years before receiving a diagnosis, treating each flare-up as an isolated problem rather than recognizing the pattern.

The exact mechanism that triggers HS remains incompletely understood, but researchers have identified several factors that significantly increase risk. Genetics play a substantial role—roughly one-third of people with HS have a close relative with the same condition. Hormonal shifts matter too; the condition often emerges after puberty and some women experience predictable flare-ups tied to their menstrual cycles. Obesity increases risk through both mechanical friction and systemic inflammation. Smoking is strongly associated with HS, affecting both immune function and skin inflammation. Age and gender also factor in: HS typically begins in early adulthood and occurs more frequently in women than men. Some research suggests certain ethnic groups may be more susceptible, though more evidence is needed. Immune system dysregulation—the body's inflammatory response misfiring—appears central to the condition's development. Having one or more of these risk factors does not guarantee HS will develop, and people without obvious risk factors can still acquire it.

The early warning signs are deceptively simple: recurring boils, lumps, or abscesses that appear and disappear in the same locations. Many people delay seeking care, hoping the pattern will break. This delay carries real consequences. When HS goes untreated, the damage compounds. Permanent scarring develops. Sinus tracts—tunnels beneath the skin that sometimes connect multiple lesions—form and become prone to infection, potentially requiring antibiotics or surgical intervention. The ongoing inflammation and scarring can restrict movement and take a measurable toll on mental health. In rare cases, untreated HS has been linked to serious complications including fistulas and an elevated risk of squamous cell carcinoma in affected areas.

The critical window for intervention is early. HS does not resolve on its own, which means waiting is not a strategy—it is a choice to accept preventable scarring. A dermatologist should be consulted when lumps persist without healing, recur frequently, cause significant discomfort, show signs of infection like redness or pus drainage, or when the emotional weight of the condition begins to affect daily life.

Management begins with lifestyle adjustments. Maintaining a healthy body weight reduces friction and systemic inflammation. Quitting smoking removes a major inflammatory driver. Loose-fitting clothing minimizes skin rubbing. Gentle cleansing of affected areas with antiseptic two to three times daily can reduce bacterial load. Avoiding hot, humid environments helps keep flare-ups at bay. These changes alone do not cure HS, but they create conditions for other treatments to work more effectively.

Medical options range from topical to surgical. Antibiotic creams and washes address mild inflammation. Oral antibiotics, taken long-term, manage inflammation and prevent secondary infections. For women, hormonal treatments—oral contraceptives or anti-androgens like spironolactone—can regulate hormonal influences on the condition. Biologic inhibitors, approved for moderate to severe cases, can substantially reduce symptoms and prevent flare-ups. Immunosuppressants are reserved for severe disease. Corticosteroids, given orally or by injection, provide short-term relief during acute flare-ups. For abscesses causing acute pain, incision and drainage offers temporary relief but is not a long-term solution. Laser treatments can reduce lesions and hair growth in affected areas. In severe cases, surgical approaches become necessary: wide excision of affected skin can prevent recurrence in treated areas, while a procedure called deroofing removes the top layer of skin over tunnels and abscesses to promote healing.

No single treatment works for everyone. Most people require a combination approach, adjusted over time based on response and tolerance. The goal is not cure—HS is chronic—but rather reducing flare-up frequency and severity, minimizing scarring, and preserving quality of life. This requires ongoing partnership with a dermatologist who monitors the condition and adapts the treatment plan as needed. The difference between early intervention and delayed care is often the difference between managing a condition and living with permanent disfigurement.